Neurology
Within the neurology area, BioTrends syndicated reports currently focus primarily on the competitive multiple sclerosis market — capturing perceptions and attitudes regarding both disease modifying agents (DMAs) and symptomatic management products. Pulling from across the wide spectrum of BioTrends reports, we are able to keep clients informed regarding any changes over time in the attitudes, trial, and usage of both DMAs and symptomatic products, capture timely feedback regarding the impact of new product launches (e.g. Gilenya, Ampyra) within this quickly evolving market, and drill down into patient-level data provided both by neurologists and by patient themselves.
If you don't find a topic or disease in our list of publications, please call 610-321-9400 or email us so that we can guide you to related or upcoming coverage or to discuss a customized project.